Lilly’s weight-loss pill shows better blood sugar control in late-stage trials

Lilly’s weight-loss pill shows better blood sugar control in late-stage trials

Eli Lilly‘s experimental weight-loss pill showed superior blood sugar control in diabetic patients across two late-stage trials, the company said on Wednesday, as it seeks to widen its lead in the rapidly growing market for GLP-1 drugs. The oral drug, orforglipron, is designed to mimic the appetite-suppressing GLP-1 hormone targeted by the company’s blockbuster injection…

Read More
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say

Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say

Novo Nordisk‘s and Eli Lilly‘s blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity and its complications, a major European medical association advised on Thursday. Semaglutide, the active ingredient in Novo’s Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be…

Read More